# A Phase 2 in Adult Subjects With Hereditary Angioedema

> **NCT06846398** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Argo Biopharmaceutical Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** BW-20805
- **DRUG:** BW-20805
- **DRUG:** BW-20805

## Key facts

- **NCT ID:** NCT06846398
- **Lead sponsor:** Shanghai Argo Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846398, "A Phase 2 in Adult Subjects With Hereditary Angioedema". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06846398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*